SAN DIEGO, Aug. 4, 2016 /PRNewswire/ -- Ambrx, Inc., a clinical stage biotechnology company that discovers and develops first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates, today announced that it has closed...
SAN DIEGO, March 21, 2016 - Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) announced today that they initiated First-In-Human phase I clinical trial with ARX788, Ambrx's most advanced internally developed site-specific...
SAN DIEGO, Nov. 16, 2015 Ambrx today announced the appointment of Yong-Jiang Hei, M.D., Ph.D. as Chief Medical Officer (CMO) reporting directly to CEO, Tiecheng "Alex" Qiao. With nearly...
SAN DIEGO and TAIZHOU CITY, China, April 29, 2014 – Ambrx Inc. and Zhejiang Hisun Pharmaceutical Company Ltd. (SSE Code: 600267) today announced a collaboration for the development and commercialization...
